ProductLife Group and Gens & Associates Alliance Drives Innovation into Life Science Information Management & Compliance
Life sciences outsourcing and consulting services specialist ProductLife Group (PLG) has announced a strategic partnership with management consultancy Gens & Associates. The move is part of PLG’s plan to develop a comprehensive ecosystem of best-of-breed service providers which, together, can transform the efficiency, competitiveness and compliance of life sciences organisations in an increasingly complex and challenging market.
PLG specialises in helping pharmaceutical and cosmetics companies with their regulatory, safety, medical evaluation and monitoring and GxP quality challenges across Europe. Gens & Associates helps companies shape their information management and organisational strategies and is a leading independent advisory practice for the life sciences industry. It has been conducting incisive industry research for the past 8 years and is the primary source of regulatory information management benchmarking data.
Explaining the joint agenda, Adam Sherlock, chief of strategic development at PLG, says: “The challenges facing life sciences companies today are so intense and so wide-reaching that it is no longer plausible that a single service provider can meet all of the requirements, or do this well. The alliance with Gens & Associates marks the coming together of two thought leaders to drive real change and innovation within the industry.”
Gens & Associates’ expertise complements ProductLife’s own consultancy and advisory practice, in the areas of process optimisation, information management, organisational design, and particularly regulatory information management (RegIM) and enterprise content management (ECM). The partnership will give PLG clients access to a broad and deep international network of consultants with complementary skills. “It will extend our reach and the range of services we can provide to clients,” Adam explains. “It also gives our clients access to respected benchmarking surveys and industry insight.”
Clients of Gens & Associates, meanwhile, will benefit from PLG’s deep relationships with organisations across Europe. Of the partnership founder Steve Gens says: “Our combined client base now has double the skill base and range of services to draw on, and the comfort of knowing the partnership will last and can take their information management and compliance initiatives to the next level.”
“The timing of this partnership is significant,” PLG’s Adam adds. “Most organisations are either in the process of implementing RegIM systems, processes and infrastructure or are re-evaluating frameworks they have put in place over the past 5 years. The underlying technology has reached a level of maturity and capability now which the industry has been demanding for some time, so that there is now a real possibility that RegIM can deliver the productivity and efficiency gains it has always promised. Working together, ProductLife Group and Gens & Associates are in a position to add tangible and timely value for our combined client base in this and all of the related information compliance areas.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance